Research · Sep 3, 2026
[FMS] Fresenius Medical Care Thesis 2026: Care Enablement Margin Cycle Drives US Dialysis Recovery
Fresenius Medical Care AG (NYSE: FMS) FY2025 revenue ~€19.5-20.5B (~$21-22B; +0-5%) with adj. EPS ~€2.40-2.80 (~$1.30-1.50 per ADR) reflecting continued post-2024 ~340,000+ aggregate dialysis patients globally + selected continued post-2024 ~$15-16B aggregate Care Delivery revenue (~75%+ aggregate revenue mix; selected primary US + selected various international dialysis services) + selected continued post-2024 ~$5-5.5B aggregate Care Enablement revenue (~25% aggregate revenue mix; selected primary dialysis products + selected various) + selected post-November 2022 selected various FME25 ~$0.7B aggregate cumulative cost savings program completion + selected continued post-November 2022 selected various Helen Giza turnaround under continued President + CEO Helen Giza since November 2022 (~3-year tenure as Fresenius Medical Care CEO). The world's largest dialysis services + dialysis products company. Founded 1996 as Fresenius Medical Care AG via 1996 Fresenius AG + National Medical Care merger; selected post-1912 Fresenius founding heritage; selected post-1996 NYSE ADR listing; selected post-November 2022 Helen Giza CEO appointment + FME25 program. Headquartered in Bad Homburg Germany; ~120,000+ employees globally with ~€19.5-20.5B revenue. Two primary business segments: Care Delivery (~75%+ ~€15-16B), Care Enablement (~25% ~€5-5.5B). Geographic mix: US ~55%+ + EMEA ~25% + LatAm + APAC ~20%. US dialysis cycle + Care Delivery: ~340,000+ aggregate dialysis patients; ~37%+ aggregate US dialysis market share alongside DaVita ~37%+. Care Enablement margin cycle: ~13-15% Care Enablement operating margin trajectory toward ~15-17%; FME25 ~$0.7B cumulative cost savings completion. President + CEO Helen Giza since November 2022 (~3-year tenure); CFO Martin Fischer. Capital return: ~€1.44 annual dividend FY2025 (~+5-10% growth; ~25-year continuous dividend track); modest opportunistic buybacks; aggregate capital return ~€0.4-0.5B; net leverage ratio ~3.0-3.5x; investment-grade Baa3/BBB credit rating. FY2026 thesis: US dialysis Care Delivery cycle + Care Enablement margin recovery + selected continued post-November 2022 FME25 turnaround + ~€1.44 annual dividend + ~25-year continuous dividend track + ~€0.4-0.6B aggregate annual capital return + selected continued post-November 2022 deleveraging + selected potential post-deleveraging dividend acceleration. Risks: US dialysis reimbursement risk, DaVita competition, FME25 turnaround execution, US Medicare + international reimbursement, EUR/USD volatility.